[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:triple-negative-breast-cancer":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":310,"states":318},"Triple-negative breast cancer",69,61,[8,16,22,29,35,41,48,55,61,68,74,79,85,91,97,103,109,115,121,127,133,139,145,151,157,162,168,174,180,186,192,198,204,210,216,222,227,233,239,245,251,257,262,268,274,280,286,292,298,304],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06966700","A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)",[12],"Phase 3","RECRUITING","2026-08-26T02:15:01.639696Z","2026-07-05T05:32:16.724482Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT05633654","Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05\u002FAFT-65 OptimICE-RD\u002FGBG 119\u002FNSABP B-63)",[12],"2026-08-26T02:15:37.042762Z","2026-06-16T05:54:07.910708Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT05989828","A2-ESO-1 TCR-Engineered T Cells for Relapsed\u002FRefractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer",[26],"Phase 1","2026-08-26T02:16:21.385056Z","2026-05-29T15:36:40.167133Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT06347068","Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells",[26],"2026-08-26T02:18:23.582895Z","2026-05-05T02:47:14.272026Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT06959537","A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)",[26],"2026-08-26T02:17:55.355429Z","2026-05-05T02:43:29.697183Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":46,"content_modified":47},"NCT06238921","Sacituzumab Govitecan and Zimberelimab w\u002FSRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases",[45],"Phase 1\u002FPhase 2","2026-08-26T02:19:00.742020Z","2026-05-05T02:43:29.665620Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":53,"content_modified":54},"NCT06435351","Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy",[52],"Early Phase 1","2026-08-26T02:15:46.655893Z","2026-05-05T02:43:29.524933Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT07190469","PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer",[26],"2026-08-26T02:18:34.622081Z","2026-05-05T02:43:29.049063Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":66,"content_modified":67},"NCT04677816","Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients",[65],"Phase 2","2026-08-26T02:18:48.678868Z","2026-05-05T02:43:28.811543Z",{"nct_id":69,"title":70,"phases":71,"status":13,"updated_at":72,"content_modified":73},"NCT06827613","A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors",[45],"2026-08-26T02:18:43.501109Z","2026-05-05T02:43:28.740603Z",{"nct_id":75,"title":76,"phases":77,"status":13,"updated_at":33,"content_modified":78},"NCT02926690","Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer",[26],"2026-05-05T02:43:28.544945Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT04468061","Sacituzumab Govitecan +\u002F- Pembrolizumab in Metastatic TNBC",[65],"2026-08-26T02:17:19.710918Z","2026-05-05T02:43:28.510179Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT06908928","A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs",[26],"2026-08-26T02:19:13.549512Z","2026-05-05T02:43:28.483795Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT06134375","A Study of Tetrathiomolybdate (TM) Plus Capecitabine",[45],"2026-08-26T02:18:22.309547Z","2026-05-05T02:43:28.297682Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT06246968","A Study of Pembrolizumab and Cryoablation in People With Breast Cancer",[26],"2026-08-26T02:17:57.997171Z","2026-05-05T02:43:28.218870Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":107,"content_modified":108},"NCT06637306","Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer",[52],"2026-08-26T02:16:14.341106Z","2026-05-05T02:43:28.118603Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":113,"content_modified":114},"NCT04434040","Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)",[65],"2026-08-26T02:18:11.042248Z","2026-05-05T02:43:27.827881Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":119,"content_modified":120},"NCT06353997","Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II\u002FIII TNBC Patients",[65],"2026-08-26T02:16:20.336282Z","2026-05-05T02:43:27.595158Z",{"nct_id":122,"title":123,"phases":124,"status":13,"updated_at":125,"content_modified":126},"NCT06926920","A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer",[45],"2026-08-26T02:15:20.225313Z","2026-05-05T02:43:27.509015Z",{"nct_id":128,"title":129,"phases":130,"status":13,"updated_at":131,"content_modified":132},"NCT04768426","Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer",[65],"2026-08-26T02:18:52.966503Z","2026-05-05T02:43:27.433022Z",{"nct_id":134,"title":135,"phases":136,"status":13,"updated_at":137,"content_modified":138},"NCT06318897","Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer",[65],"2026-08-26T02:19:19.975067Z","2026-05-05T02:43:27.334247Z",{"nct_id":140,"title":141,"phases":142,"status":13,"updated_at":143,"content_modified":144},"NCT06460298","ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer",[45],"2026-08-26T02:17:59.904383Z","2026-05-05T02:43:27.105465Z",{"nct_id":146,"title":147,"phases":148,"status":13,"updated_at":149,"content_modified":150},"NCT07066189","Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC",[],"2026-08-26T02:19:27.519777Z","2026-05-05T02:43:27.087021Z",{"nct_id":152,"title":153,"phases":154,"status":13,"updated_at":155,"content_modified":156},"NCT06245889","PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC",[65],"2026-08-26T02:17:05.172421Z","2026-05-05T02:43:27.058531Z",{"nct_id":158,"title":159,"phases":160,"status":13,"updated_at":20,"content_modified":161},"NCT07069595","PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease",[65],"2026-05-05T02:43:26.906414Z",{"nct_id":163,"title":164,"phases":165,"status":13,"updated_at":166,"content_modified":167},"NCT03671044","A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients",[12],"2026-08-26T02:15:50.539717Z","2026-05-05T02:43:26.771068Z",{"nct_id":169,"title":170,"phases":171,"status":13,"updated_at":172,"content_modified":173},"NCT07341867","Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype",[26],"2026-08-26T02:18:46.137046Z","2026-05-05T02:43:26.720722Z",{"nct_id":175,"title":176,"phases":177,"status":13,"updated_at":178,"content_modified":179},"NCT05528133","Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer",[65],"2026-08-26T02:18:44.395098Z","2026-05-05T02:35:31.778620Z",{"nct_id":181,"title":182,"phases":183,"status":13,"updated_at":184,"content_modified":185},"NCT07276880","Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer",[65],"2026-08-26T02:17:20.511551Z","2026-04-29T02:57:57.174693Z",{"nct_id":187,"title":188,"phases":189,"status":13,"updated_at":190,"content_modified":191},"NCT06845319","Anthracycline-Free Neoadjuvant Chemoimmunotherapy for Triple Negative Breast Cancer Patients",[65],"2026-08-26T02:16:23.080181Z","2026-04-29T02:57:57.154353Z",{"nct_id":193,"title":194,"phases":195,"status":13,"updated_at":196,"content_modified":197},"NCT04348747","Dendritic Cell Vaccines Against Her2\u002FHer3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer",[65],"2026-08-26T02:15:14.574786Z","2026-07-05T05:32:16.794666Z",{"nct_id":199,"title":200,"phases":201,"status":13,"updated_at":202,"content_modified":203},"NCT07029399","A Study With NKT5097 for Adults With Advanced\u002FMetastatic Solid Tumors",[26],"2026-08-26T02:15:53.461103Z","2026-06-16T05:54:07.931783Z",{"nct_id":205,"title":206,"phases":207,"status":13,"updated_at":208,"content_modified":209},"NCT07340541","Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies",[65],"2026-08-26T02:17:47.813245Z","2026-05-05T02:43:29.495871Z",{"nct_id":211,"title":212,"phases":213,"status":13,"updated_at":214,"content_modified":215},"NCT06799065","First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer",[26],"2026-08-26T02:19:06.150683Z","2026-05-05T02:43:28.304090Z",{"nct_id":217,"title":218,"phases":219,"status":13,"updated_at":220,"content_modified":221},"NCT05064280","Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases",[65],"2026-08-26T02:15:03.757872Z","2026-05-05T02:43:27.860046Z",{"nct_id":223,"title":224,"phases":225,"status":13,"updated_at":46,"content_modified":226},"NCT06577987","Safety\u002FEfficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies",[26],"2026-05-05T02:43:27.665400Z",{"nct_id":228,"title":229,"phases":230,"status":13,"updated_at":231,"content_modified":232},"NCT06249048","Phase 1\u002F2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab",[45],"2026-08-26T02:16:38.897933Z","2026-05-05T02:43:26.920220Z",{"nct_id":234,"title":235,"phases":236,"status":13,"updated_at":237,"content_modified":238},"NCT07115043","A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors",[45],"2026-08-26T02:15:56.561131Z","2026-05-05T02:43:29.700642Z",{"nct_id":240,"title":241,"phases":242,"status":13,"updated_at":243,"content_modified":244},"NCT05983432","Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors",[26],"2026-08-26T02:16:56.877406Z","2026-05-05T02:43:28.678419Z",{"nct_id":246,"title":247,"phases":248,"status":13,"updated_at":249,"content_modified":250},"NCT05208762","A Study of PF-08046054\u002FSGN-PDL1V in Advanced Solid Tumors",[26],"2026-08-26T02:17:52.450442Z","2026-05-05T02:43:28.548027Z",{"nct_id":252,"title":253,"phases":254,"status":13,"updated_at":255,"content_modified":256},"NCT07182149","A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors",[26],"2026-08-26T02:18:08.005333Z","2026-05-05T02:43:28.535783Z",{"nct_id":258,"title":259,"phases":260,"status":13,"updated_at":178,"content_modified":261},"NCT06270706","A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors",[26],"2026-05-05T02:43:28.480860Z",{"nct_id":263,"title":264,"phases":265,"status":13,"updated_at":266,"content_modified":267},"NCT05076760","MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors",[26],"2026-08-26T02:19:07.104270Z","2026-05-05T02:43:28.200826Z",{"nct_id":269,"title":270,"phases":271,"status":13,"updated_at":272,"content_modified":273},"NCT06465069","A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors",[26],"2026-08-26T02:16:39.977107Z","2026-05-05T02:43:27.622410Z",{"nct_id":275,"title":276,"phases":277,"status":13,"updated_at":278,"content_modified":279},"NCT06150664","A Phase 1 of CTX-8371 in Patients With Advanced Malignancies",[26],"2026-08-26T02:19:09.651016Z","2026-05-05T02:43:27.515153Z",{"nct_id":281,"title":282,"phases":283,"status":13,"updated_at":284,"content_modified":285},"NCT05746897","A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors",[26],"2026-08-26T02:16:58.658552Z","2026-05-05T02:43:27.404012Z",{"nct_id":287,"title":288,"phases":289,"status":13,"updated_at":290,"content_modified":291},"NCT05005403","Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan",[26],"2026-08-26T02:18:26.129155Z","2026-05-05T02:43:27.253319Z",{"nct_id":293,"title":294,"phases":295,"status":13,"updated_at":296,"content_modified":297},"NCT06399757","A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors",[45],"2026-08-03T03:48:46.663572Z","2026-05-05T02:43:27.110534Z",{"nct_id":299,"title":300,"phases":301,"status":13,"updated_at":302,"content_modified":303},"NCT06795412","Phase 1\u002F2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors",[45],"2026-08-26T02:15:25.633039Z","2026-05-05T02:43:26.952051Z",{"nct_id":305,"title":306,"phases":307,"status":13,"updated_at":308,"content_modified":309},"NCT04282044","Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies",[26],"2026-08-26T02:16:05.813655Z","2026-05-05T02:43:26.932270Z",[311,315],{"biomarker":312,"count":313,"slug":314},"ERBB2 Gene",3,"erbb2-gene",{"biomarker":316,"count":313,"slug":317},"HLA Class I Histocompatibility Antigen, A-2 Alpha Chain","hla-class-i-histocompatibility-antigen-a-2-alpha-chain",[319,323,327,331,335,339,342,345,349,353,357,360,364,367,371,374,377,381,384,388,391,394,398,401],{"state":320,"count":321,"slug":322},"Texas",29,"texas",{"state":324,"count":325,"slug":326},"California",24,"california",{"state":328,"count":329,"slug":330},"Florida",20,"florida",{"state":332,"count":333,"slug":334},"New York",18,"new-york",{"state":336,"count":337,"slug":338},"Massachusetts",16,"massachusetts",{"state":340,"count":337,"slug":341},"Ohio","ohio",{"state":343,"count":337,"slug":344},"Virginia","virginia",{"state":346,"count":347,"slug":348},"Tennessee",14,"tennessee",{"state":350,"count":351,"slug":352},"Michigan",13,"michigan",{"state":354,"count":355,"slug":356},"North Carolina",11,"north-carolina",{"state":358,"count":355,"slug":359},"Utah","utah",{"state":361,"count":362,"slug":363},"Connecticut",10,"connecticut",{"state":365,"count":362,"slug":366},"Missouri","missouri",{"state":368,"count":369,"slug":370},"Georgia",9,"georgia",{"state":372,"count":369,"slug":373},"Illinois","illinois",{"state":375,"count":369,"slug":376},"Pennsylvania","pennsylvania",{"state":378,"count":379,"slug":380},"Arizona",8,"arizona",{"state":382,"count":379,"slug":383},"Colorado","colorado",{"state":385,"count":386,"slug":387},"Minnesota",7,"minnesota",{"state":389,"count":386,"slug":390},"South Carolina","south-carolina",{"state":392,"count":386,"slug":393},"Washington","washington",{"state":395,"count":396,"slug":397},"Indiana",6,"indiana",{"state":399,"count":396,"slug":400},"New Jersey","new-jersey",{"state":402,"count":403,"slug":404},"Iowa",5,"iowa"]